Cape Fear BioCapital — Full Portfolio
6 tracked investments · listed companies and verified rows first
Eldec is a biotechnology company developing peptide-based therapeutics targeting SPLUNC1's modulation of Orai1 activity, with lead programs ELD615 and ELD607 for lung diseases such as cystic fibrosis and non-CF bronchiectasis.
BiotechHealthtechChapel Hill, US
Robert Tarran(Co-founder, President & Chief Scientific Officer)Saira Ahmad(Co-founder)Flori Sassano(Co-founder)Robert Schotzinger(Executive Officer, Director)Robert J. Schotzinger(Chairman & Chief Executive Officer)Robert Hughes(Chief Financial Officer)
Early-stage oncology company developing a breakthrough siRNA platform to target undruggable cancer pathways.
BiotechPittsboro, US
Michael Dombeck(Executive Officer, Director)Chad V. Pecot(Executive Officer, Director)
BoardJoe McMahon(Director)Sue Mahony(Director)
Incyclix Bio develops precision cancer treatments targeting the CDK family of enzymes to restore cell cycle control in tumors, including CDK targets beyond CDK4/6 such as CDK2.
BiotechHealthtechDurham, US
Patrick Roberts(Executive Officer and member of the Board of Managers.)
BoardFredric N. Eshelman(Executive Officer and member of the Board of Managers.)Sid Subramony(Member of the Board of Managers.)Norman Sharpless(Member of the Board of Managers.)
Co-investorsEshelman Ventures, LLCHatteras Venture PartnersHatteras
iOrganBio builds CellForge, an AI- and automation-driven platform for engineering and manufacturing human cells and organoids.
Co-investorsFirst Star VenturesHartmann CapitalAlix VenturesIndieBioSOSV
Ten63 develops drug-discovery technology that combines generative chemistry with quantum-accurate molecular simulation, including BEYOND (a large quantum chemistry model) and Sentinel (a virtual CSO for target selection), to design therapeutics against previously undruggable targets.
AI & Machine LearningBiotechDeep TechDurham, US
Mark A. Hallen(Executive Officer, Director)Marcel Frenkel(Executive Officer, Director)Damien Petty(Director)Jia Wei Xu(Director)
Co-investorsDFJ DragonFundDraper AssociatesDuke Capital PartnersAlexandriaHatterasHatteras Venture Partners+2 more
Thoracic Innovations is a medical device company that develops products using computer-aided design, rapid prototyping, and 3D printing, with a focus on the cardiothoracic and thoracic clinical area.
BiotechHardwareHealthtechMedical DevicesChapel Hill, US
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.